Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Hyperhidrosis Therapeutics Pipeline Analysis Report 2017 - Clinical Trials & Results, Patent, Designations and Collaborations -

Research and Markets
Posted on: 06 Mar 18

The "Hyperhidrosis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments" report has been added to's offering.

The study analyzed that the hyperhidrosis therapeutics pipeline comprises of approximately 12 drug candidates in different stages of development.

Allergan Plc, TheraVida Inc., and GlaxoSmithKline Plc have one drug candidate each in the Phase II development for the treatment of hyperhidrosis. Glycopyrronium tosylate is the only drug candidate that has the Phase III stage of development for the treatment of hyperhidrosis. Majority of the pipeline drug candidates are being developed using the topical route of administration.

Major players in the market are putting more emphasis on targeting cholinergic receptors. The drug candidates used for the treatment of hyperhidrosis, act on cholinergic receptors and block its activity that interfere with sweating. For instance, Glycopyrronium tosylate, a Phase III drug candidate by Dermira, Inc. acts topically and blocks the cholinergic receptor.

In March 2015, Kaken Pharmaceutical Co., Ltd. and Brickell Biotech, Inc. entered in an agreement concerning the exclusive licensing and joint development of BBI-4000. Under the terms of agreement Brickell Biotech, Inc. agreed to conduct a Phase IIb clinical trial of BBI-4000 in the U.S. for patients with primary focal hyperhidrosis..

Some of the key players developing drugs for the treatment of hyperhidrosis include Dermira, Inc., Allergan plc, TheraVida Inc. and others.

Report Segmentation

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered

Chapter 1. Research Background

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

Chapter 5. Hyperhidrosis Therapeutics Pipeline Analysis by Phase (2017)

Chapter 6. Clinical Trials Analysis

Chapter 7. Competitive Landscape

Chapter 8. Company Profiles

For more information about this report visit

View source version on

Business Wire

Last updated on: 06/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.